Unigestion Holding Sa Vertex Pharmaceuticals Inc Transaction History

Unigestion Holding Sa

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $1.08 Million - $1.33 Million	2,743 New	2,743 $1.29 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $25 Million - $29.9 Million	-72,806 Reduced 96.37%	2,743 $1.12 Million
Q3 2023 Oct 31, 2023	BUY	$338.18 - $362.46 $10,145 - $10,873	30 Added 0.04%	75,549 $26.3 Million
Q2 2023 Jul 27, 2023	SELL	$314.42 - $351.91 $9.32 Million - $10.4 Million	-29,652 Reduced 28.19%	75,519 $26.6 Million
Q1 2023 May 09, 2023	SELL	$283.23 - $323.1 $15,577 - $17,770	-55 Reduced 0.05%	105,171 $33.1 Million
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $2.33 Million - $2.62 Million	8,161 Added 8.41%	105,226 $30.4 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $25.4 Million - $28.3 Million	92,577 Added 2062.77%	97,065 $28.4 Million
Q2 2022 Aug 03, 2022	BUY	$234.96 - $292.55 $1.05 Million - $1.31 Million	4,488 New	4,488 $1.27 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $250,482 - $334,068	-1,210 Closed	0 $0
Q3 2020 Nov 10, 2020	SELL	$255.65 - $303.1 $279,936 - $331,894	-1,095 Reduced 47.51%	1,210 $329,000
Q2 2020 Aug 05, 2020	BUY	$225.48 - $295.8 $519,731 - $681,819	2,305 New	2,305 $670,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Unigestion Holding Sa, based on Form 13F filings with the SEC.

Stay updated on Unigestion Holding Sa with notifications on news.